期刊
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
卷 9, 期 4, 页码 275-279出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.2165/11590170-000000000-00000
关键词
-
The literature indicates that the expenditure on orphan drugs will be increasing over the coming years. The market for orphan drugs has inherent market characteristics that sometimes result in high prices. The aim of this study was to analyse whether awarding orphan designation status has an influence on the price setting of drugs for rare disease indications. To this effect, prices of designated orphan drugs were compared with other non-designated drugs for rare disease indications. We identified 28 designated orphan drugs and 16 comparable non-designated drugs for rare disease indications for which we collected official hospital prices (per defined daily dose) in Belgium in 2010. Orphan-designated drugs had a higher median price (epsilon 138.56 [interquartile range; IQR epsilon 406.57]) than non-designated drugs (epsilon 16.55 [IQR epsilon 28.05]) for rare disease indications (p < 0.01). In conclusion, our results suggest that awarding orphan designation status in itself is associated with higher prices for drugs for rare disease indications. In order to gain full insight into orphan drug pricing mechanisms, future research should focus on collecting information about the different factors influencing orphan drug pricing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据